REG - Sareum Holdings PLC - Intention to grant notice - EU patent for SDC-1802

Sareum HoldingsAnnouncement

15/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211215:nRSO6584Va&default-theme=true

RNS Number : 6584V  Sareum Holdings PLC  15 December 2021

Sareum Holdings plc

("Sareum" or the "Company")

Sareum receives 'Intention to Grant' Notification from the European Patent
Office for its TYK2/JAK1 inhibitor SDC-1802

Cambridge, UK, 15 December 2021 - Sareum Holdings plc (AIM: SAR), the
specialist drug development company delivering targeted small molecule
therapeutics to improve the treatment of cancer and autoimmune diseases,
announces that the European Patent Office has issued an Intention to Grant
notice for a patent in respect of an invention associated with Sareum's
proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme.

The patent (EPO Patent Application no. 17787186.0) will protect the SDC-1802
molecule and pharmaceutical preparations thereof as a therapeutic to treat
TYK2-dependent T-cell acute lymphoblastic leukaemia (T-ALL - a cancer of a
particular type of white blood cell called a T lymphocyte) by inhibiting TYK2
kinase. This programme is in preclinical development.

The Company expects that the patent will be formally granted within four
months, subject to certain formalities being completed.

Sareum's CSO, Dr John Reader, commented:

"Our aim is to build broad robust patent protection for our proprietary
TYK2/JAK1 inhibitor candidates as they advance through their respective
development programmes, to ensure that Sareum retains full value in these
programmes as part of its business development discussions. We are pleased
therefore to receive this 'Intention to Grant' notice from EPO around our
patent application for SDC-1802 as a potential treatment for T-ALL. We expect
to complete the formalities that would lead to a full grant of this patent in
due course."

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                          01223 497 700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                               020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow / David Dible                 020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPALFDDFFFA